COMPASS THERAPEUTICS

Compass Therapeutics to Participate in Upcoming Investor Events

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in Upcoming Investor Events

30 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

03 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

22 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in Upcoming Investor Events

01 Jun 2023 09:06:24 By Nasdaq GlobeNewswire

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

04 May 2023 07:30:01 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ

26 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

19 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

28 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

15 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

02 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

19 Jan 2023 16:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

06 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

15 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

01 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

22 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

09 Nov 2022 08:00:00 By Nasdaq GlobeNewswire

Compass Therapeutics to Present at Upcoming Investment Conferences

08 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Compass Therapeutics Announces $80 Million Private Placement

02 Nov 2022 08:06:54 By Nasdaq GlobeNewswire

Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)

11 Oct 2022 07:00:02 By Nasdaq GlobeNewswire